Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Spesolimab - Boehringer Ingelheim

Next Previous
Drug Profile

Spesolimab - Boehringer Ingelheim

Alternative Names: BI 655130; Spesolimab-sbzo; SPEVIGO

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Anti-inflammatories; Antipsoriatics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 36 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Generalised pustular psoriasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Generalised pustular psoriasis
  • Phase III Pyoderma gangrenosum
  • Phase II/III Hidradenitis suppurativa; Netherton Syndrome; Ulcerative colitis
  • Phase II Crohn's disease; Palmoplantar pustulosis
  • Discontinued Atopic dermatitis

Most Recent Events

  • 27 Mar 2026 Efficacy and adverse events data from a phase IIb trial in Generalised pustular psoriasis presented at the American Academy of Dermatology annual Meeting 2026 (AAD-2026)
  • 27 Mar 2026 Efficacy and adverse event data from phase II Effisayil ON trial in Generalised pustular psoriasis released by LEO Pharma
  • 29 Jan 2026 Boehringer Ingelheim terminates a phase II/III Lunsayil LTE trial in Hidradenitis suppurativa in Canada, Singapore, Malaysia, Lithuania, South Korea, Japan, Bulgaria, Argentina, Spain, Poland, Germany, France, Australia, USA (SC) due to sponsor decision (NCT06241573)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top